glp-1 receptor agonist drugs in development research Frontiers Issue 42: GLP-1 RA Drug

In addition, this report is a consensus of expert endocrinologists representing South Asian countries including India, Pakistan, Bangladesh, Nepal, Sri Lanka, Afghanistan and the Maldives on essential recommendations related to the use of GLP-1 RAs in a real-world scenario.

Learn About Their Benefits and Effectiveness.

While newly approved pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show efficacy, their clinical utility remains constrained by dose-dependent gastrointestinal complications, underscoring the urgent need for safer alternatives

Explore evidence-based natural alternatives to GLP1: fermentable fiber, protein timing, targeted supplements like berberine, probiotics, exercise and Tonums oral Motus trial results

Conclusions We found no signal of disproportionate reporting of an association between GLP-1RA use and SSIBs